Antipsychotic drug action: antagonism, inverse agonism or partial agonism

Trends in Pharmacological Sciences

Volumn 29, Issue 6, 2008, Pages 314-321

  Strange, Philip G ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; ARIPIPRAZOLE; BROMOCRIPTINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PRECLAMOL; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

CELL STIMULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG INVERSE AGONISM; HUMANS; PIPERAZINES; QUINOLONES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 44549087928     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.03.009     Document Type: Review

References (55)

1. Laruelle M., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl Acad. Sci. U. S. A. 93 (1996) 9235-9240
2. Abi-Dargham A., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl Acad. Sci. U. S. A. 97 (2000) 8104-8109
3. Abi-Dargham A., and Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur. Psychiatry 20 (2005) 15-27
4. Abi-Dargham A., and Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9 (2003) 404-416
5. Honey G., and Bullmore E. Human pharmacological MRI. Trends Pharmacol. Sci. 25 (2004) 366-374
6. Jones P.B., et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63 (2006) 1079-1087
7. Lieberman J.A., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
8. Strange P.G. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 53 (2001) 119-133
9. 3 receptor antagonist with both presynaptic and limbic selectivity. J. Pharmacol. Exp. Ther. 280 (1997) 83-97
10. Meltzer H.Y., et al. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251 (1989) 238-246
11. Millan M.J. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J. Pharmacol. Exp. Ther. 295 (2000) 853-861
12. Busatto G.F., and Kerwin R.W. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. J. Psychopharmacol. 11 (1997) 3-12
13. Carlsson A., et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 237-260
14. Swainston Harrison T., and Perry C.M. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64 (2004) 1715-1736
15. El-Sayeh H.G., et al. Aripiprazole for schizophrenia. Systematic review. Br. J. Psychiatry 189 (2006) 102-108
16. Lahti A.C., et al. Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J. Neural Transm. 105 (1998) 719-734
17. Lahti A.C., et al. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol. Psychiatry 43 (1998) 2-11
18. 2 receptor partial agonist. Eur. J. Pharmacol. 552 (2006) 36-45
19. Cosi C., et al. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur. J. Pharmacol. 535 (2006) 135-144
20. Strange P.G. Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br. J. Pharmacol. 153 (2008) 1353-1363
21. 2 receptors?. J. Neural Transm. Gen. Sect. 92 (1993) 213-220
22. Gilliland S.L., and Alper R.H. Characterization of dopaminergic compounds at hD2short, hD4.2 and hD4.7 receptors in agonist-stimulated [35S]GTPγS binding assays. Naunyn Schmiedebergs Arch. Pharmacol. 361 (2000) 498-504
23. Gazi L., et al. Pharmacological analysis of a dopamine D(2Short):G(αo) fusion protein expressed in Sf9 cells. FEBS Lett. 545 (2003) 155-160
24. Watts V.J., et al. Selective activation of Gαo by D2L dopamine receptors in NS20Y neuroblastoma cells. J. Neurosci. 18 (1998) 8692-8699
25. 35S] binding. J. Pharmacol. Exp. Ther. 285 (1998) 119-126
26. 3 receptor. J. Neural Transm. 103 (1996) 1163-1175
27. 2 dopamine receptors. Br. J. Pharmacol. 121 (1997) 731-736
28. Wilson J., et al. Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation. J. Neurochem. 77 (2001) 493-504
29. 1 dopamine receptor. Mol. Pharmacol. 52 (1997) 1137-1149
30. 2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs. J. Pharmacol. Exp. Ther. 304 (2003) 380-390
31. 3 partial agonist. J. Pharmacol. Exp. Ther. 315 (2005) 1278-1287
32. 2 dopamine receptors. Br. J. Pharmacol. 145 (2005) 34-42
33. Urban J.D., et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320 (2006) 1-13
34. Svensson K., et al. (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn Schmiedebergs Arch. Pharmacol. 334 (1986) 234-245
35. 4.4 receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 127 (1999) 1135-1144
36. Lin H., et al. Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor. Br. J. Pharmacol. 149 (2006) 291-299
37. Hjorth S., et al. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology (Berl.) 81 (1983) 89-99
38. Meller E., et al. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol. Pharmacol. 31 (1987) 592-598
39. 2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274 (1995) 329-336
40. Milligan G., and Bond R.A. Inverse agonism and the regulation of receptor number. Trends Pharmacol. Sci. 18 (1997) 468-474
41. 2 receptor following repeated treatment in the rat striatum. Eur. J. Pharmacol. 321 (1997) 105-111
42. 2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Brain Res. Mol. Brain Res. 55 (1998) 285-292
43. 2 receptor, but the rodent metabolite displays antagonist properties. Eur. J. Pharmacol. 546 (2006) 88-94
44. Newman-Tancredi A., et al. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr. Opin. Investig. Drugs 8 (2007) 539-554
45. 2 receptor-mediated signaling pathways. Neuropsychopharmacology 32 (2007) 67-77
46. 2 receptor: (S)-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1, Gi2 and Gi3. Mol. Pharmacol. 71 (2007) 1349-1359
47. 2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity. Br. J. Pharmacol. 138 (2003) 775-786
48. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am. J. Psychiatry 152 (1995) 173-178
49. Kapur S., et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 514-520
50. 2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl.) 175 (2004) 473-480
51. Laruelle M., et al. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 46 (1999) 56-72
52. 3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27 (2002) 248-259
53. Mamo D., et al. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J. Psychiatry 164 (2007) 1411-1417
54. Strange P.G. The structure and mechanism of neurotransmitter receptors. Implications for the structure and function of the central nervous system. Biochem. J. 249 (1988) 309-318
55. 2 receptor partial agonist. Expert Opin. Investig. Drugs 16 (2007) 771-775